Cardiovascular effects of diuretics;KARDIOVASKULARE WIRKUNGEN VON DIURETIKA

Nieren- und Hochdruckkrankheiten

Volumn 25, Issue 4, 1996, Pages 154-161

  Knauf, H ^a   Hasenfuss, G ^b   Mutschler, E ^c  

^a St Bernward Krankenhaus ^*  (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

antihypertensive effect; early and late hemodynamic effects of diuretics; left ventricular hypertrophy; total peripheral resistance

Indexed keywords

DIURETIC AGENT; LOOP DIURETIC AGENT; PROSTAGLANDIN;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DIURESIS; DIURETIC ACTIVITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART PRELOAD; HEMODYNAMICS; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR RESISTANCE;

EID: 0029938437     PISSN: 03005224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Achhammer I., P. Metz: Low dose loop diuretics in essential hypertension - experience with torasemide. Drugs 41 (Suppl. 3), 80-91 (1991).
2. Aleksandrow D., W. Wysznacka, J. Gajewski: Influence of chlorothiazide upon arterial responsiveness to norepinephrine in hypertensive subjects. New Engl. J. Med. 261, 1052 (1959).
3. Ames R.P.: Indapamide vs. thiazides: a meta-analysis comparing antihypertensive response and lipid effects. Am. J. Hypertens. 8, 45 (1995).
4. Bennett W.M., W.J. McDonald, E. Kuehnel, M.N. Hartnett, G.A. Porter: Do diuretics have antihypertensive properties independent of natriuresis? Clin. Pharmacol. Ther. 22, 499-504 (1977).
5. Biagi R.W., B.N. Bapat: Furosemide in acute pulmonary oedema. Lancet I, 849 (1967).
6. Bhatia M.L., I. Singh, S.C. Manchanda, P.K. Khanna, S.B. Roy: Effect of furosemide on pulmonary blood volume. Brit. Med. J. II, 551 (1969).
7. Bolte H.D., Th. v. Armin, E. Erdmann: Myokardiale Natrium-Kalium-ATPase und Wirkungen von Diuretika am Myokard. In: Krück F., A. Schrey: Diuretika. Wolf, München 1981, 80.
8. Brater D.C.: Resistance to diuretics: Emphasis on pharmacological perspective. Drugs 22, 477 (1981).
9. van Breemen C., P. Aaronson, R. Loutzenhiser: Sodium-calcium interactions in mammalian smooth muscle. Pharmacol. Rev. 30, 167-208 (1979).
10. Cantiello H., J. Copello, A. Muller, L. Mikulic, M.F. Villami: Effect of bumetanide on potassium transport and ionic composition of the arterial wall. Amer. J. Physiol. 251, F537-F546 (1986).
11. Conway J., R. Lauwers: Hemodynamic and hypertensive effects on long-term therapy with chlorothiazide. Circulation 21, 21 (1960).
12. Cruickshank J., J. Lewis, V. Moore, C. Dodd: Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J. Hum. Hypertens. 6, 85-90 (1992).
13. Dahlof B., K. Pennert, L. Hansson: Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am. J. Hypertens. 5, 95-110 (1992).
14. Delbarre B., G. Delbarre, A. Feger: Rôle des prostaglandines dans le mécanisme de l'indapamide. Arch. Mal Coeur 83, 109-121 (1990).
15. Dikshit K., J.K. Vyden, J.S. Forrester et al.: Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. New Engl. J. Med. 288, 1087 (1973).
16. Finnerty E A., M. Davidov, N. Kakaviatios: Relation of sodium balance to arterial pressure during drug-induced saluresis. Circulation 37, 175 (1968).
17. Francis G.S., R.M. Siegel, S.R. Goldsmith, M.T. Olivari, T.B. Levine, J.N. Cohn: Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann. intern. Med. 103, 1-6 (1985).
18. Freis E.D., A. Wanko, H.W. Schnaper, E.D. Frohlich: Mechanism of the altered blood pressure responsiveness produced by chlorothiazide. J. Clin. Invest. 39, 1277 (1960).
19. Frohlich E.D., W.H. Schnaper, I.M. Wilson, E.D. Freis: Hemodynamic alterations in hypertensive patients due to chlorothiazide. New Engl. J. Med. 262, 1261 (1960).
20. Gottdiener J., D. Reda, A. Notargiacomo, B. Materson: Comparison of monotherapy effects on LV mass regression in mild to moderate hypertension: differences between short and long-term therapy. J. Am. Coll. Cardiol. 19, 85A (1992).
21. Guyton A.C.: Interstitial fluid pressure: II. Pressure-volume curves of interstitial space. Circ. Res. 16, 452-460 (1965).
22. Haddy E.J., M.B. Pamnani, B.T. Swindall, J. Johnston, E.J. Cragoe: Sodium channel blockers are vasodilators as well as natriuretic and diuretic agents. Hypertension 7 (Suppl. I), I121-I126 (1985).
23. Hansen J.: Hydrochlorothiazide in the treatment of hypertension. Acta med. Scand. 317, 1983 (1968).
24. Hasenfuß G., C. Holubarsch, C. Herzog, H. Knauf, H. Spahn, E. Mutschler, H. Just: Influence of cardiac function on the diuretic and hemodynamic effects of the loop diuretic piretanide. Clin. Cardiol. 10, 83-88 (1987).
25. Johnston G.D., W.R. Hiatt, A.S. Nies et al.: Factors modifying the early nondiuretic vascular effects of furosemide in man. The possible role of renal prostaglandines. Circ. Res. 53, 630-635 (1983).
26. Johnston G.D., D.P. Nicholls, W.J. Leahey, M.D. Finch: The effects of captopril on the acute vascular responses to furosemide in man. Clin. Sci. 65, 359 (1983).
27. Johnston G.D., D.P. Nicholls, W.J. Leahey, P.C. O'Connor, M.B. Finch: The acute venodilator effects of furosemide in man. The importance of furosemide-stimulated renin release. Brit. J. Clin. Pharmac. 17, 192P (1984).
28. Kaplan N.M.: Clinical hypertension, 3. ed. Williams & Wilkins, Baltimore 1982.
29. Kaplan N.M., J.G. Silah: The effect of angiotensin II on blood pressure in humans with hypertensive disease. J. clin. Invest. 43, 659 (1964).
30. Leth A.: Changes in plasma and extracellular fluid volumes in patients with essential hypertension during long-term treatment with hydrochlorothiazide. Circul. 42, 479 (1970).
31. Lund-Johansen P.: Hemodynamic changes in long-term diuretic therapy of essential hypertension. Acta med. Scand. 187, 509 (1970).
32. Mace P.J.E., WA. Littler, D.R. Glover, D.B. Rowlands, T.H. Stallard: Regression of left ventricular hypertrophy in hypertension: comparative effects of three different drugs. J. Cardiovasc. Pharmacol. 7, S52-S55 (1985).
33. Margini F., A.P. Niarchos: Ineffectiveness of sublingual nitroglycerin in acute left ventricular failure in the presence of massive peripheral edema. Amer. J. Cardiol. 45, 841-847 (1980).
34. Margini F., A.P. Niarchos: Hemodynamic effects of massive peripheral edema. Amer. Heart J. 105, 90-97 (1983).
35. Mendlowitz M., N. Naftchi, S.E. Gitlow: The effect of chlorothiazide and its congeners on the digital circulation in normotensive subjects and in patients with essential hypertension. Ann. NY Acad. Sci. 88, 964 (1960).
36. Mironneau J., J.P. Savineaii, C. Mironneau: Compared effects of indapamide, hydrochlorothiazide and chlorthalidone on electrical and mechanical activities in vascular smooth muscle. Europ. J. Pharmacol. 75, 109-113 (1981).
37. Moser M., J.F. Setaro: Antihypertensive drug therapy and regression of left ventricular hypertrophy: a review with a focus on diuretics. Eur. Heart J. 12, 1034-1039 (1991).
38. Mügge M., W. Schmitz, H. Scholz: Negative inotropic effects of aldosterone antagonists in isolated human and guinea-pig ventricular heart muscle. Klin. Wschr. 62, 717 (1984).
39. Nauman d'Alnoncourt C., M. Hornberger, B. Lüderitz: Interaktionen von Triamteren und Herzglykosiden am Erregungsleitungssystem des Herzens. Verh. Dtsch. Ges. Inn. Med. 82, 1236 (1976).
40. Noble R.E., E.L. Webb, J.C. Godfrey, M. Zisblatt, R.A. Vukovich, E.S. Neiss: Indapamide in the stepped-care treatment of obese hypertensive patients. Curr. Med. Res. Opin. 8 (Suppl. 3), 93-104 (1983).
41. Ofili E.O., D.N. Uy, R. Castello, J.S. Vrain et al.: Effectiveness of treatment on left ventricular mass reduction in elderly subjects with isolated systolic hypertension. Circulation 85 (Suppl. 2), 137 (1992).
42. Orgison J.L.: Failure of chlorothiazide to influence tissue electrolytes in hypertensive and non-hypertensive nephrectomized dogs. Proc. Soc. exp. Biol. Med. 110, 161-164 (1962).
43. Philipp T.H., A. Distler, U. Cordes: Sympathetic nervous system and blood pressure control in essential hypertension. Lancet II, 959 (1978).
44. Plante G.E., C. Robillard: Indapamide in the treatment of essential arterial hypertension: results of a controlled study. Curr. Med. Res. Opin. 8, 59-66 (1983).
45. Reid W.D., J.H. Laragh: Sodium and potassium intake, blood pressure and pressor response to angiotensin. Proc. Soc. exp. Biol. Med. 120, 26 (1965).
46. Schenk K.E., G. Biamino, E.v. Leitner, R. Schröder: Wirkung von Nitroglycerin, Furosemid und Etacrynsäure auf die Hämodynamik in Ruhe und unter ergometrischer Belastung bei Patienten mit koronarer Herzerkrankung. Z. Kardiol. 64, 15 (1976).
47. Schröder R., B. Ramdohr, U. Hüttemann, K.P. Schüren: Direkte positiv-inotrope Herzwirkung von Aldactone (Spironolacton, Canrenoat-Kalium). Dtsch. med. Wschr. 41, 1535 (1972).
48. Shah S., I. Khatri, E.D. Freis: Mechanism of antihypertensive effect of thiazide diuretics. Amer. Heart J. 95, 611 (1978).
49. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 265, 3255 (1991).
50. Strauer B.E.: Das Hochdruckherz, 3. Aufl. Springer, Berlin 1991.
51. Strauer B.E.: Evidence for a positive inotropic effect of aldadiene (-K, -Na) on the isolated ventricular myocardium. Klin. Wschr. 50, 387 (1972).
52. Tamura A., T. Sato, T. Fuji: Antioxidant activity of indapamide and its metabolite. Chem. Pharm. Bull. 38, 255-257 (1990).
53. Tanz R.D., C.F. Kerby: The inotropic action of certain steroids upon isolated cardiac tissue, with comments on steroidal cardiotonic structure-activity relationship. J. Pharmacol. exp. Ther. 131, 56 (1961).
54. Uehara Y., H. Shirahase, T. Nagata, T. Ishimitsu, T. Morishita, S. Morishita, S. Osumi, H. Matsuoka, T. Sugimoto: Radical scavenging effects of indapamide on prostacyclin generation in vascular smooth muscle cells in rats. Hypertension 15, 216-224 (1990).
55. Valette H., J.L. Hebert, I.E. Apoi: Acute haemodynamic effects of a single intravenous dose of piretanide in congestive heart failure. Europ. J. Clin. Pharmacol. 24, 163-167 (1983).
56. Waldorff S., J. Berning, J. Buch, E. Steiness: Systolic time intervals during spironolactone treatment of digitalized and non-digitalized patients with ischemic heart disease. Europ. J. Clin. Pharmacol. 21, 269 (1982).
57. Weber J.J.: Intravenous triamterene in the treatment of acute digitalis intoxication. Clin. Pharmacol. Ther. 13, 868 (1972).
58. Weidmann P.: Recent pathogenic aspects in essential hypertension and hypertension associated with diabetes mellitus. Klin. Wschr. 58, 1971 (1980).
59. Wilson I.M., E.D. Freis: Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide. Circulation 20, 1028 (1959).
60. Winer B.M.: The antihypertensive action of benzothiazine. Circulation 23, 211 (1961).